Shree Remedies Peer Comparison

BSE: 540737

₹633.05

₹5.60 (0.89%)

As on 26-Oct-2026IST

Market cap

₹809 Cr

Revenue (TTM)

₹99 Cr

P/E Ratio

52.4

P/B Ratio

4.9

Div. Yield

0 %

Edit

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	809	29,435	27,409	25,981	24,746
Revenue (₹ Cr)	99	3,564	1,462	9,205	1,936
Net Profit (₹ Cr)	15.44	414.00	387.35	-371.81	288.22
Net Margin (%)	15.09	11.23	26.01	-3.93	14.79
RoE (%)	9.76	8.38	25.18	-3.85	29.77
Price to Earnings	52.43	71.97	70.97	--	85.86
Price-To-Book	4.93	5.85	15.89	3.25	18.44

Income Statement (₹ Cr)

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	98.98	3,564.00	1,461.80	9,205.28	1,935.80
Total Income	102.29	3,686.00	1,489.25	9,449.59	1,948.58
Total Expenditure	67.90	2,792.00	919.25	8,195.15	1,485.56
EBITDA	31.08	772.00	542.56	1,010.13	450.24
Depreciation	10.49	226.00	37.68	857.51	50.83
EBIT	20.59	546.00	504.88	152.62	399.41
Interest	2.94	217.00	3.77	342.73	40.84
Other Income	3.31	122.00	27.45	244.31	12.78
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	20.95	463.00	528.56	-162.68	371.35
Provision for Tax	5.51	49.00	141.21	209.13	83.14
Profit after Tax	15.44	414.00	387.35	-371.81	288.22

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	162.97	4,940.00	1,653.56	8,162.62	1,288.82
Minority Interest	0.00	-5.00	-1.13	0.00	0.00
Non-Current Liabilities	23.03	1,712.00	42.40	5,044.14	202.03
Current Liabilities	21.69	1,622.00	230.82	4,758.28	835.87
Total Liabilities	--	8,578.00	1,983.96	17,723.32	2,326.71

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	81.06	5,343.00	1,026.85	10,211.52	519.60
Current Assets	85.86	2,606.00	881.27	7,191.66	1,681.81
Total Assets	--	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	--	2,125.00	26.49	5,495.48	259.37
Net Current Assets	64.17	984.00	650.46	2,433.38	845.94
Contingent Liabilities	--	768.26	17.25	95.72	19.09

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	--	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	--	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	--	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	--	95.00	30.33	787.59	78.39

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	--	6.79	32.42	1.24	29.22
ROE (%)	9.76	8.38	25.18	-3.85	29.77
ROA (%)	7.73	4.94	21.93	-2.21	24.77
EBIT Margin (%)	20.80	15.32	34.54	1.66	20.63
Net Margin (%)	15.09	11.23	26.01	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	-8.76	18.37	40.90	0.78	46.65
EBIT Growth (%)	-27.56	252.26	124.50	-70.53	62.13
Net Profit Growth (%)	-29.39	377.85	104.15	-1,383.43	89.49
EPS Growth (%)	-29.37	1,001.33	42.32	-484.84	78.60
Book Value Growth (%)	--	13.47	26.03	0.33	144.31

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	52.42	73.87	70.97	-83.03	84.54
Price / Book Value	4.93	5.85	15.89	3.25	18.44
Dividend Yield (%)	0.00	0.00	0.07	0.00	0.10
EV/EBITDA	26.19	40.02	50.15	29.82	54.77
Market Cap (₹ Cr)	--	19,071.62	20,944.75	18,108.89	12,753.19

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.13	0.31	0.02	0.53	0.11
Short term debt to equity ratio	--	0.09	0.02	0.09	0.05
Current Ratio	3.96	1.61	3.82	1.51	2.01
Quick Ratio	2.85	1.06	2.82	0.87	1.14
Interest Coverage	8.12	3.13	141.16	0.53	10.09

	Shree Remedies	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	32.90	16.50	24.80	23.44	26.28
Asset Turnover	0.50	0.43	0.83	0.55	1.66
Receivable days	--	58.75	88.98	78.20	40.13
Inventory Days	--	75.82	56.04	93.30	60.29
Payable days	--	186.21	99.95	226.14	232.47
Cash Conversion Cycle	--	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.